52 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2034. from the record
Of the 19 now held by other companies, 6 name Nanthealth Inc. as their current owner, and 13 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2034
Next term end
35
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2038 · High confidence
Also notable
Ends Nov 2038 · High confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Feb 2040 · High confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends Jan 2037 · High confidence
Also notable
Ends Sep 2039 · High confidence
Digital Histopathology and Microdissection
US 10,607,343
Cited by 34 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Cancer Neoepitopes
US 11,421,016
Cited by 28 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Distributed Machine Learning Systems, Apparatus, and Methods
US 11,461,690
Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2038.
Genome Explorer System to Process and Present Nucleotide Variations in Genome Sequence Data
US 10,347,361
The most cited patent in this portfolio, cited by 60 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2034.
Classification Based on Characterization Analysis Methods and Systems
US 11,195,062
Granted 2021. Computed term ends 2040.
Systems And Methods For High-Accuracy Variant Calling
US 11,393,557
Granted 2022. Computed term ends 2037.
Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor
US 10,532,089
Granted 2020. Computed term ends 2037.
Cancer Score for Assessment and Response Prediction from Biological Fluids
US 11,810,672
Granted 2023. Computed term ends 2039.
Formerly held, still cited
Notable
Ends Dec 2035 · High confidence
Cited by 72 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by Nanthealth, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 20, 2026 · next Dec 18
- 2 fees due Jan 2 to 9, 2027 · next Jan 2
- 1 fee due Feb 8, 2027The maintenance fee for Iterative Discovery of Neoepitopes and Adaptive Immunotherapy and Methods Therefor (US 11,717,564) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for A Method of Treating a Tumor in a Patient Based on an Immune Gene Expression Signature (US 11,756,651) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 3 fees due May 5 to 21, 2027 · next May 5
- 3 fees due Jul 7 to 16, 2027 · next Jul 7
- 1 fee due Aug 20, 2027The maintenance fee for Systems And Methods For Genetic Analysis Of Metastases (US 11,908,588) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Digital Histopathology and Microdissection (US 10,607,343) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 4 fees due Oct 2 to 14, 2027 · next Oct 2
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 35 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,347,361 | Genome Explorer System to Process and Present Nucleotide Variations in Genome Sequence Data In force · High confidence | In force | High confidence | |
| US 10,323,285 | Proteomics Analysis and Discovery through DNA and RNA Sequencing, Systems and Methods In force · High confidence | In force | High confidence | |
| US 10,620,184 | SRM/MRM Assay for the Cyclin-Dependent Kinase Inhibitor 2A (p16) protein In force · Medium confidence | In force | Medium confidence | |
| US 10,525,040 | Compositions and Methods of RIT1 Inhibition In force · High confidence | In force | High confidence | |
| US 10,736,884 | Compositions and Methods of RIT1 Inhibition held by Nant Holdings IP, LLC In force · High confidence | In force | High confidence | |
| US 12,404,490 | AGGF1 Immunogenic Compositions In force · High confidence | In force | High confidence | |
| US 12,793,811 | Systems And Methods For High-Accuracy Variant Calling In force · Medium confidence | In force | Medium confidence | |
| US 10,339,274 | Viral Neoepitopes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,623,001 | Compositions And Methods For Viral Cancer Neoepitopes In force · High confidence | In force | High confidence | |
| US 12,080,382 | Viral Neoepitopes and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 52: 19 patents in force now held by others · 25 applications pending · 53 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.